Summit Therapeutics Shares Drop Following FDA Rejection of Ivonescimab for Lung Cancer

Summit Therapeutics (SMMT) experienced a significant pre-market sell-off of over 20% after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its flagship cancer drug, ivonescimab. The rejection specifically concerns the drug's application for treating EGFR-mutated non-small cell lung cancer (NSCLC). While the drug met primary endpoints for progression-free survival in the HARMONi clinical trial, it failed to meet the strict statistical threshold for overall survival required by regulators. Despite this setback, analysts suggest the company maintains strong fundamentals. Summit possesses nearly $630 million in cash reserves and significant backing from partners like Akeso (AKESF) and AstraZeneca (AZN). The company is currently pivoting toward larger 'first-line' treatment markets and has 17 ongoing late-stage clinical trials to bolster its long-term commercial potential.

By TMF Breakfast News · Motley Fool ·

Summit Therapeutics Shares Drop Following FDA Rejection of Ivonescimab for Lung Cancer

Tickers: $AZN $SMMT

Topics: biotechnology drug approval FDA rejection lung cancer treatment stock price plunge

Read the full article at Motley Fool

Part of the story Summit Therapeutics Shares Drop Following FDA Rejection of Ivonescimab Combination Therapy (4 articles)

More Health news